Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.
Inna SmalleyVincent LawClayton WyattBrittany EverndenBin FangJohn M KoomenEric A WelshRobert J B MacaulayPeter A ForsythKeiran S M SmalleyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These analyses identified proteomic/transcriptional signatures in the CSF of patients who succumbed to LMM. We further showed that the CSF from patients with LMM has the potential to modulate BRAF inhibitor responses and may contribute to drug resistance.See related commentary by Glitza Oliva and Tawbi, p. 2083.